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ABSTRACT 
Biobanks are collections of biological material and related files gathered and stored for 
clinical or research purposes. Here, we investigated the questions raised during the 
evaluation of biobanks by biomedical Research Ethics Committees (RECs), particularly in 
the context of genetic research. We sent a questionnaire to all RECs in France to survey 
their concerns and the ethical criteria used when evaluating research involving the storage 
of biological samples. Most of the RECs think that they should be consulted to evaluate the 
constitution of biobanks. The proportion of RECs of this opinion depended on whether the 
biobank is being constituted in the absence of an associated research project (initially 
created for clinical purposes or for undefined research) (14/28), whether the biobank is 
being constituted for research use (21/28) or whether an existing research biobank is being 
re-used (19/28). Views diverged concerning the way ethics principles are applied, showing 
that REC evaluations of biobanks might be formalised at each of the following steps: 
constitution, use and re-use. In this paper, we suggest concrete elements that could be 
integrated into the application of the new French law concerning the protection of the 
human beings participating in research as well as into international recommendations.  
 
Key words: Biobanks, Research Ethics Committee, Biomedical Research, Informed 
Consent, Human Biological Resources, Genetic Databases. 
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1. INTRODUCTION 
Historical grounds, together with the development of biomedical research involving 
humans, led to the institution of Ethics Committees. These committees were officially 
created in 1975 in the Helsinki Declaration [29].  
In France, a law passed in 1988 [13] led to the constitution of research ethics committees 
(RECs) for the protection of persons participating in biomedical research. There are now 48 
such committees, each serving a defined geographical area. These committees are 
independent in their selection of members and in their finances. Members are drawn from 
groups representative of medical research, medical practitioners, universities, various major 
disciplines, and law. The recommendations formulated by the committees are transmitted to 
the Ministry of Health, which can independently review an opinion when judged necessary 
[13, 14]. The role of the committees, as defined by law, is to evaluate the validity of 
research, particularly as concerns: the protection of participants, informed consent of 
participants, methods of obtaining consent, financial compensation, general relevance of the 
project and whether the available means and the qualifications of the investigators involved 
are appropriate to meet the aims. 
All biomedical research must be approved by an REC. It is not clear whether the evaluation 
of biobanks is part of the mission of the RECs and if so, in what way. A biobank can be 
defined as a group of biological samples (or biological by-products) that may consist of 
solid tissues, blood, saliva, or any other tissue or fluid containing nucleated cells. The 
biological samples are associated with files, often computerised, that may include the origin 
of the donors, clinical data and biological data. [4, 6, 11]. These data may be identified, 
identifiable, directly anonymous or anonymised [18]. The way in which the files are 
handled differs according to the type of research. The term “biobank” covers all of the 
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activities concerning the management of human biological samples and files including their 
transfer and access.  
Following the development of biobanks, French official reports suggested that RECs should 
evaluate the constitution and storage of biological samples. In 1994, the Louisot Report [22] 
stated that “...the constitution of the collection…requires the opinion of the REC” and in 
1998, the report of the French National Consultative Ethics Committee (CCNE) stated that 
“…this agreement will take into account measures involved in the collection, storage and 
abusive use (such as use in the context of employment, insurance …) of samples and any 
information concerning them” [5].  
A number of studies have highlighted the ethical and legal issues raised by the constitution 
of biobanks, including the organisational and medical responsibilities [3, 8, 9, 10, 23, 24]. 
We have previously evaluated [4, 27] how the French RECs feel they are and should be 
involved in the constitution and use of biobanks, which ethical rules they believe are 
essential for the protection of persons and to what extent this is integrated into current 
practice. The aim of the present study was to identify current difficulties in the functioning 
of the committees. We used a questionnaire to examine whether the RECs consider that the 
constitution of a biobank requires their approval. Twenty-five of the 28 RECs that answered 
think that they should be consulted for the constitution of biobanks, but in practice, only 18 
conduct such evaluations. The RECs believe that they should, and do, consider the content 
of the consent form, the information given to participants and confidentiality. Interestingly, 
elements such as uses of a biobank, its fate at the end of the study and the ways in which 
research results are communicated to participants are not evaluated although RECs think 
that they should be.  
The goal of the present study is to define the roles and means of the RECs in the evaluation 
of biobanks. Our results focus first on the way RECs evaluate different types of biobank in 
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the context of human genetics research, and second, on proposals that can be made to 
formalise these evaluations.  
 
2. METHODS 
Data were collected from the questionnaire between 2001 and 2002 and analysed in 2003. 
We used a questionnaire with open and closed questions that had been validated by a 
multidisciplinary team working in the Laboratory of  Medical Ethics at the Paris 5 Faculty 
of Medicine (see table I). It was approved by the national REC conference chairman and by 
six previous REC members. A letter was sent with the questionnaire to explain the aims of 
the study, the definition used for biobanks, references to French recommendations [5, 22] 
and laws relevant to the study. The questionnaire was sent with a stamped self-addressed 
envelope to the president of each of the 48 French RECs. Replies to the closed questions 
were analysed using Excel software. For open questions, the content of the text was 
analysed by the research team with expertise in genetics and bioethics to extract relevant 
citations highlighting the issues addressed here. The proposals concerning the evaluation of 
biobanks by RECs were complied by using the replies to this open questions, discussions 
with experts (CCPPRB members, CCNE members, research team members, institutional 
members), our expertise in the field [2, 4, 9, 21, 27] and by analysing international literature 
(publications, reports and proposals). 
 
3. RESULTS  
3.1 Questionnaire survey  
Twenty-eight of the 48 RECs (58.3%) completed the questionnaire. This response rate is 
similar to those obtained in similar studies [15, 26]. This rate indicates that many RECs are 
concerned and want to contribute to the evaluation of practices.  
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Question 1 asked whether the RECs should be consulted prior to the constitution of 
biobanks. RECs were almost unanimous (21/28) in answering that they should be consulted 
for the constitution of any biobank as part of a defined research project. Most of them 
(19/28) believe that an REC should be consulted for every new research project using 
samples from an existing research biobank either for a similar study or for a different type 
of study. Opinions were divided (14/28) concerning the constitution of biobanks without an 
associated research project at the origin. 
Question 2 asked whether the RECs feel a special responsibility concerning their mission in 
the evaluation of biobanks. Two contrasting attitudes were expressed:  
- The strict limitation of the competences of the RECs as stated by the law, the main 
argument being that the multiplication of opinions leads to increased inertia. 
- An extended view, which recommends that this field of research should be part of 
the REC’s field of competence and responsibility despite their current lack of 
resources (time and human resources). 
The following questions dealt with cases the RECs encountered in practice. 
To question 3, 14 of the 28 RECs replied that they knew precisely how many files they had 
handled involving the constitution and use of a biobank.  
In question 4, only 7 of these 14 RECs reported the percentage of files handled that 
concerned biobanks (between 5% and 10%). The percentage has not changed over the last 
three years. Three members of REC spontaneously reported that some biomedical research 
projects involve biobanks that are not visible in the project proposals presented to the 
RECs. For example, clinical projects can include sampling and storage activities that are not 
explicitly called a biobank by the investigators.  
Answers to question 5 show that fourteen of the 28 RECs believed that biobanks are being 
used in their geographical region without their prior evaluation. 
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Question 6 asked whether the RECs have dealt with files concerning the constitution of 
biobanks without an associated research project. This seems to be a rare event.  
In response to question 7, the three RECs concerned explained that they didn’t feel 
competent to evaluate this kind of biobank, but that they had a role in helping the 
investigators to handle ethical issues. 
To question 8, 25 of the 28 RECs replied that they would agree to participate in a study 
aiming to analyse the files they handle concerning the constitution or the use of biobanks. 
This shows their interest in evaluating their own practices. 
 
3.2 Proposals  
On the basis of the literature [1, 3, 5, 7, 10, 11, 12, 18, 19, 20, 25] and our results [4, 9, 21, 
27], we conclude that it is necessary to formalise the role of the committees in this field 
(Figure 1). The life of a biobank can be broken down into four stages: (1) constitution, (2) 
storage, (3) first use and (4) fate, including (4a) destruction or anonymisation, (4b) distant 
use and (4c) delocalisation to an organisation specialised in the conservation, transfer and 
supply of biobanks.  
Three main situations should be considered by RECs for evaluation:  
- the constitution of any biobank: samples collected for biomedical research, 
requalified clinical samples (for example blood samples collected for medical care 
purposes re-used for research) and samples collected from different geographical 
areas (national or international), whether from private or public institutions for their 
own research programme or for any activity involving the conservation, transfer and 
supply of biobanks.  
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- the setting up of any research protocol (primary or secondary use) involving use of a 
pre-existing biobank. In a number of cases the constitution of the biobank and the 
setting up of the research project will be associated in the evaluation by the REC.  
- any event affecting the biobank (transfer, destruction, anonymisation). 
To simplify the evaluation procedures two different REC evaluation procedures could be 
organised: an initial procedure at the constitution of the biobank whether or not this is 
associated with a research project, and a simplified procedure (follow-up) for all other 
cases.  
At the constitution step, three fundamental points should be evaluated:  
- the information given to the donor 
- the modalities for consent before sample collection 
- the relevance of the scientific research requiring the creation of the biobank. 
To define more precisely the analysis of these points, the following elements should be 
considered from now on: time given to the participant between information and consent, 
possibility to withdraw from the study at any time, estimated duration of storage, level of 
confidentiality for personal data, choice of the population studied in the context of the 
relevance of the scientific project (to avoid unnecessary inclusion of high-risk populations 
and to optimise existing biobanks) and fate of a biobank. 
Whenever a biobank is used or re-used, the following series of items should be evaluated: 
- Concordance with the initial consent: new orientation of scientific choices, 
geographical transfer, modification of the level of confidentiality. If these conditions 
are not fulfilled, the REC should propose to seek new consent or to make the 
samples anonymous. 
- Result feedback: in all cases, global result feedback to the participants should be 
considered, as should the modalities by which this could be achieved. RECs could 
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play a role in evaluating how the research team addresses these questions and their 
practical application. 
- Level of confidentiality: a modification may be required in some cases e.g. for a 
new study distinct from the first scientific project. Anonymisation of the samples 
will prevent any further data from being added to the biobank and the possibility of 
individual feedback. The role of the REC could be to evaluate the pertinence of such 
choices by considering the initial information and consent as well as the obstacles to 
obtaining new consent relevant to the new project. 
 
4. DISCUSSION 
Our findings indicate that the RECs generally feel that their opinion is necessary for the 
constitution of biobanks, particularly DNA banks, and that they have a particular 
responsibility regarding the re-use of existing samples [27]. Unlike classical therapeutic 
trials, new biomedical activities are not necessarily evaluated by a REC. This was the case 
for ICSI (Intracytoplasmic Sperm Injection), which was not subject to any control by RECs 
[26]. Therefore, it may be necessary to define how the use of tools such as DNA biobanks 
in new practices may be potentially harmful to the individual to ensure appropriate means 
of protection.  
Our results show that there is a difference between the activity of RECs in practice and the 
way they consider their role. This could be explained by the existence of different situations 
related to the constitution and use of biobanks, and by a lack of regulations adapted to each 
case. 
According to a report published in 2001 and to our results [15], it appears that the RECs are 
not always consulted for the constitution of biobanks, particularly when no research project 
is associated. Nevertheless, on the basis of our results, we consider that ethical evaluation is 
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essential to ensure that samples and associated data are collected, stored and used correctly, 
that they remain confidential and that their fate at the end of the study is traced [21]. 
Accordingly, recent international propositions recommended the evaluation of biobanks by 
RECs. The European Society of Human Genetics stated that “when it [DNA banking] is for 
research use, ethical committee oversight is required” [11]. In the International Declaration 
on Human Genetic Data, the United Nations Educational, Scientific and Cultural 
Organisation (UNESCO) also proposed that “Ethics committees at institutional or local 
levels should be consulted as regard to collections in their application to specific research 
projects” [28]. Finally, the revised French bioethics laws published in August 2004 specify 
that RECs must be consulted every time a biobank is constituted or re-used for a purpose 
different from that covered by the initial consent [14, 17]. This law also specifies that RECs 
must evaluate the way ethical principles are applied in practice by considering: "the quality 
of the information given to the participants, the methods for collecting consent, and the 
ethical and scientific relevance of the project". Therefore, this law proposes that the 
committees give an opinion at each essential phase of the life of a biobank: constitution, 
primary use, and re-use with novel scientific finalities. This can be considered as a major 
breakthrough in the field of biobanks. Rules and guidelines to assist the practical setting up 
of the general principles written in the law must now be established by taking into 
consideration results from studies like this one. For example, such recommendations should 
allow more clear and concrete definition of concepts from the law such as quality of 
information. We feel it is essential to ensure that all ethical issues concerning biobanks are 
considered  
In conclusion, our results and proposals might contribute towards the development of 
national and international guidelines [21]. If they are to be effective, these guidelines must 
be adapted to the practical reality of routine use. If based upon international grounds, the 
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guidelines would allow a better view of the functioning of these precious tools for the 
development of scientific and medical knowledge.  
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Table 1: Summary of the 28 answers to the questionnaire  
 
 Yes No No answered 
1/ Do you think that RECs should be consulted to give an opinion on 
- The constitution of a biobank without an associated research 
project at the origin  
- The constitution of a  biobank with an associated research project 
- The re-use of a biobank already being used  in a research project 
o For a similar study 
o For a different type of study 
 
14 
 
21 
19 
12 
12 
 
9 
 
2 
4 
4 
4 
 
5 
 
5 
5 
12 
12 
2/ Official reports have suggested that ethic committees should play specific 
roles in the evaluation of biobanks? Do you feel concerned?  Comment. 
15 3 10 
3/ Do you know how many files you have treated concerning the constitution 
or use of a biobank? 
14 8 6 
4/ If yes, what percentage of the total number of files treated do these files 
represent?  
(1) 
5/ Do you think that in your geographical region, biobanks are being used 
without prior consultation by RECs? 
14 4 10 
6/ Have you ever dealt with files concerning the constitution of a biobank 
without an associated research project (for example, gathering of existing 
biological samples)? 
3 23 2 
7/ If yes, do the RECs consider themselves competent to analyse this type of 
file? Comment. 
(1) 
8/ Would you agree to take part in a study to analyse the files that your REC 
handled concerning the constitution or use of a biobank? 
25 0 3 
(1) These questions could not be treated quantitatively and are considered in the text 
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Figure 1: Steps in the constitution and use of a biobank requiring REC evaluation 
under the criteria listed  
 
 
 
 
 
 
 
 
 
 
 
 
1. Sample and data 
collection   
(New qualification of 
clinical samples, sample 
importation) 
3. Primary  use 
4a. Destruction 
or 
anonymisation 
4b. Secondary use, 
possibly by a different 
team  
REC evaluation 
REC evaluation 
REC evaluation 
- Information  
- Consent 
- Relevance of the scientific 
project 
 
With respect to the initial 
consent: 
- Consent renewal 
- Modification of the level 
of confidentiality 
- Concordance of scientific 
choices 
- Concordance of the   
research with the aims of 
the biobank 
- Reflexion about the  
modalities of result  
feedback 
- Level of confidentiality 
 
NB: Together with the evaluation by a REC, declarations should be made to the 
appropriate ministry, and authorisations concerning the treatment of individual data 
should be sought 
4c. Delocalisation to an 
organisation specialised in 
conservation, transfer and 
supply of biobanks.  
 
 
2. Storage in a research 
place or delocalisation to an 
organisation specialised in 
conservation, transfer and 
supply of biobanks 
 
 
 
